Li Gan, PhD, wants to find treatments to help patients with Alzheimer’s disease. Like most researchers, she’s hit a few major roadblocks.
When researchers like Gan find potential new drugs, it’s useful to test them on human cells to increase the chances that they will benefit patients. Historically, these tests have been conducted in cancer cells, which often don’t match the biology of human brain cells.
“The problem is that brain cells from actual people don’t survive well in a dish, so we need to engineer human cells in the lab,” explained Gan, senior investigator at the Gladstone Institutes. “But, that’s not as simple as it may sound.”
Many scientists use induced pluripotent stem cells (iPSCs) to address this issue. IPSCs are made by reprogramming skin cells or blood cells to become stem cells, which can then be transformed into any type of cell in the body. Gan uses iPSCs to produce brain cells, such as neurons or glial cells, because they are relevant to neurodegenerative disease.
Human brain cells derived from iPSCs offer great potential for drug screening. Yet, the process for producing them can be complicated, expensive, and highly variable. Many of the current methods produce cells that are heterogeneous, or different from one another, and this can lead to inconsistent results in drug screening. In addition, producing a large number of cells is very costly, so it’s difficult to scale up for big experiments.
A new platform developed in Gan’s lab will now allow scientists to overcome these constraints
A New Technique Is Born
“I came across a new method to produce iPSCs that was developed at Stanford,” said Michael Ward, MD, PhD, a former staff scientist in Gan’s lab who is now an investigator at the National Institutes of Health. “I thought that if our team could find a way to simplify and better control that approach, we might be able to improve the way we engineer human brain cells in the lab.”
Ward and his colleague Chao Wang, PhD, discovered a way to manipulate the genetic makeup of cells to produce thousands of neurons from a single iPSC. This meant that every engineered brain cell was now identical.
“I was truly motivated by our initial results,” said Gan, who is also a professor of neurology at UC San Francisco. “I had observed too much variability using the traditional methods, which made reproducing experiments quite problematic. So, the ability to produce homogeneous human brain cells was very exciting.”
The team further improved the technique to create a simplified, two-step process. This allows scientists to precisely control how many brain cells they produce and makes it easier to replicate their results from one experiment to the next.
Their technique also greatly accelerates the process. While it would normally take several months to produce brain cells, Gan and her team can now engineer large quantities of them within 1 or 2 weeks, and have functionally active neurons within 1 month.
The researchers realized this new approach had tremendous potential to screen drugs and to study disease mechanisms. To prove it, they tested it in their own research.
They applied their technique to produce human neurons by using iPSCs. Then, they developed a drug discovery platform and screened 1,280 compounds. Their goal is to identify the compounds that could lower levels of the protein tau in the brain, which is considered one of the most promising approaches in Alzheimer’s research and could potentially lead to new drugs to treat the disease.
“We showed that we can engineer large quantities of human brain cells that are all the same, while also significantly reducing the costs,” said Wang, Gladstone postdoctoral scholar. “This means our technology can easily be scaled up and can essentially be used to screen millions of compounds.”
A Powerful Tool for the Entire Scientific Community
“We have developed a cost-effective technology to produce large quantities of human brain cells in two simple steps,” summarized Gan. “By surmounting major challenges in human neuron-based drug discovery, we believe this technique will be adopted widely in both basic science and industry.”
Word of this useful new technology has already spread, and people from different scientific sectors have come knocking on Gan’s door to learn about it. Her team has shared the new method with scores of academic colleagues, some of whom had no experience with cell culture. So far, they all successfully repeated the two-step process to produce their own cells and facilitate scientific discoveries.
Details of this new technique were published on October 10, 2017, in the scientific journal Stem Cell Reports.
With some of the roadblocks out of the way, Gan hopes more discoveries will soon help the millions who suffer from Alzheimer’s disease and related conditions.
Learn more: Growing Human Brain Cells in the Lab
The Latest on: Drug discovery
[google_news title=”” keyword=”drug discovery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024on March 28, 2024 at 10:32 pm
Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The ...
- Confo Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development in Endocrine and Metabolic Diseaseson March 28, 2024 at 3:00 am
Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 million grant from Flanders ...
- New High-Throughput, AI-Based, Protein Prediction Method May Advance Drug Discoveryon March 27, 2024 at 10:45 pm
An AI method offers a new way to understand protein structures in multiple dimensions and may be a useful tool for pharmacology.
- Vietnam Artificial Intelligence (AI) in Drug Discovery Market The Mapmaker’s Guide Audience Odyssey and Market Identification Insightson March 27, 2024 at 7:55 pm
This country research report on Vietnam Artificial Intelligence (AI) in Drug Discovery Market offers comprehensive insights into the market landscape, customer intelligence, and competitive strategies ...
- New technique incorporates carbon-14 in a single step for safer, more efficient drug discoveryon March 27, 2024 at 9:18 am
McGill researchers have discovered a safer and more efficient technique for testing new drugs while they are in development.
- New technique for predicting protein dynamics may prove big breakthrough for drug discoveryon March 27, 2024 at 3:00 am
Understanding the structure of proteins is critical for demystifying their functions and developing drugs that target them. To that end, a team of researchers at Brown University has developed a way ...
- Harnessing AI for Drug Discovery: Top 3 Stocks to Watchon March 26, 2024 at 10:06 am
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Artificial intelligence (AI) spans above and beyond today’s popular ...
- How Moderna Is Embracing Data & AI To Transform Drug Discoveryon March 25, 2024 at 4:53 am
Randy Bean is a noted Author, Speaker, Founder, CEO, & Senior Advisor. While the application of data and AI holds the potential to transform and revolutionize many industries, nowhere are the life and ...
- The Future of Pharmaceuticals: How AI is Transforming Drug Discoveryon March 25, 2024 at 2:48 am
AI is changing the game in drug development! Exscientia's breakthrough in treating an 82-year-old's resistant blood cancer shows how personalized treatments and faster discoveries are now within reach ...
- bioXcelerate launches breakthrough AI tool for faster drug discoveryon March 24, 2024 at 3:53 am
Xcelerate, a new and innovative health data science division of Optima Partners Limited, has revealed a new groundbreaking AI tool, which is set to accelerate the process for identifying and ...
via Google News and Bing News